{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T12:39:58Z","timestamp":1786365598042,"version":"build-2736575974"},"reference-count":32,"publisher":"ARAN Ediciones","issue":"2","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hipertensi\u00f3n y Riesgo Vascular"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.hipert.2023.11.005","type":"journal-article","created":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T09:27:33Z","timestamp":1710840453000},"page":"95-103","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Renin\u2013angiotensin\u2013aldosterone system blockers effect in chronic kidney disease progression in hypertensive elderly patients without proteinuria: PROERCAN trial"],"prefix":"10.20960","volume":"41","author":[{"given":"A.M.","family":"Garc\u00eda-Prieto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00da.","family":"Verdalles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.P.","family":"de Jos\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Arroyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Aragoncillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Barbieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.E.","family":"Camacho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Goicoechea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"8588","reference":[{"key":"10.1016\/j.hipert.2023.11.005_bib0165","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S0140-6736(13)60687-X","article-title":"Chronic kidney disease: global dimension and perspectives","volume":"382","author":"Jha","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.hipert.2023.11.005_bib0170","first-page":"78","article-title":"Prevalence of chronic renal disease in Spain: results of the EPIRCE study","volume":"30","author":"Alfonso","year":"2010","journal-title":"Nefrolog\u00eda"},{"key":"10.1016\/j.hipert.2023.11.005_bib0175","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/sj.ki.5002343","article-title":"Chronic kidney disease as a global public health problem: approaches and initiatives \u2013 a position statement from Kidney Disease Improving Global Outcomes","volume":"72","author":"Levey","year":"2007","journal-title":"Kidney Int"},{"key":"10.1016\/j.hipert.2023.11.005_bib0180","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1053\/j.ajkd.2018.12.044","article-title":"Hypertension in CKD: core curriculum","volume":"74","author":"Ku","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.hipert.2023.11.005_bib0185","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/kisup.2012.50","article-title":"KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease: summary of recommendation statements","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.hipert.2023.11.005_bib0190","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","article-title":"Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention","volume":"382","author":"Gansevoort","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.hipert.2023.11.005_bib0195","doi-asserted-by":"crossref","first-page":"244","DOI":"10.7326\/0003-4819-139-4-200308190-00006","article-title":"Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis","volume":"139","author":"Jafar","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.hipert.2023.11.005_bib0200","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1185\/030079908X291921","article-title":"Angiotensin receptor blockers: RAAS blockade and renoprotection","volume":"24","author":"Ruilope","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.hipert.2023.11.005_bib0205","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hipert.2023.11.005_bib0210","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/S0140-6736(98)04433-X","article-title":"Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy","volume":"352","author":"Ruggenenti","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.hipert.2023.11.005_bib0215","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hipert.2023.11.005_bib0220","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hipert.2023.11.005_bib0225","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJMoa1007994","article-title":"Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes","volume":"364","author":"Haller","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hipert.2023.11.005_bib0230","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa042167","article-title":"Preventing microalbuminuria in type 2 diabetes","volume":"351","author":"Ruggenenti","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hipert.2023.11.005_bib0235","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1475-2840-1-2","article-title":"Losartan and diabetic nephropathy: commentaries on the RENAAL study","volume":"1","author":"Fisman","year":"2002","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.hipert.2023.11.005_bib0240","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/S0140-6736(05)67814-2","article-title":"Effect of inhibitors of the renin\u2013angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis","volume":"366","author":"Casas","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.hipert.2023.11.005_bib0245","doi-asserted-by":"crossref","first-page":"118","DOI":"10.5527\/wjn.v4.i1.118","article-title":"Time to re-evaluate effects of renin\u2013angiotensin system inhibitors on renal and cardiovascular outcomes in diabetic nephropathy","volume":"4","author":"Suzuki","year":"2015","journal-title":"World J Nephrol"},{"key":"10.1016\/j.hipert.2023.11.005_bib0250","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1093\/ndt\/gfp511","article-title":"The impact of stopping inhibitors of the renin\u2013angiotensin system in patients with advanced chronic kidney disease","volume":"25","author":"Ahmed","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.hipert.2023.11.005_bib0255","doi-asserted-by":"crossref","first-page":"e0170874","DOI":"10.1371\/journal.pone.0170874","article-title":"The impact of renin\u2013angiotensin system blockade on renal outcomes and mortality in pre-dialysis patients with advanced chronic kidney disease","volume":"12","author":"Oh","year":"2017","journal-title":"PLOS ONE"},{"key":"10.1016\/j.hipert.2023.11.005_bib0260","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s11255-006-0084-4","article-title":"Acute renal failure in the elderly: particular characteristics","volume":"38","author":"Musso","year":"2006","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.hipert.2023.11.005_bib0265","doi-asserted-by":"crossref","first-page":"731","DOI":"10.7326\/0003-4819-150-10-200905190-00014","article-title":"Does evidence support renin\u2013angiotensin system blockade for slowing nephropathy progression in elderly persons?","volume":"150","author":"Sarafidis","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.hipert.2023.11.005_bib0270","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hipert.2023.11.005_bib0275","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.2215\/CJN.01580210","article-title":"Effect of allopurinol in chronic kidney disease progression and cardiovascular risk","volume":"5","author":"Goicoechea","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.hipert.2023.11.005_bib0280","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.7150\/ijbs.45134","article-title":"COVID-19: what has been learned and to be learned about the novel coronavirus disease","volume":"16","author":"Yi","year":"2020","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.hipert.2023.11.005_bib0285","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1056\/NEJMoa0801369","article-title":"Treatment of hypertension in patients 80 years of age or older","volume":"358","author":"Beckett","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hipert.2023.11.005_bib0290","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1097\/00004872-200305000-00011","article-title":"The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial","volume":"21","author":"Lithel","year":"2003","journal-title":"J Hypertens"},{"key":"10.1016\/j.hipert.2023.11.005_bib0295","doi-asserted-by":"crossref","unstructured":"Bhandari S, Ives N, Brettell EA, Valente M, Cockwell P, Topham PS, et al. Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor\/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial. Nephrol Dial Transplant. 2016;31:255-61.","DOI":"10.1093\/ndt\/gfv346"},{"key":"10.1016\/j.hipert.2023.11.005_bib0300","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hipert.2023.11.005_bib0305","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(99)12323-7","volume":"355","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.hipert.2023.11.005_bib0310","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0140-6736(03)14286-9","article-title":"Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)","volume":"362","author":"Fox","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.hipert.2023.11.005_bib0315","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(03)14739-3","article-title":"Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials","volume":"362","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.hipert.2023.11.005_bib0011","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"}],"container-title":["Hipertensi\u00f3n y Riesgo Vascular"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S188918372400014X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S188918372400014X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T01:15:39Z","timestamp":1784596539000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S188918372400014X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S188918372400014X"],"URL":"https:\/\/doi.org\/10.1016\/j.hipert.2023.11.005","relation":{},"ISSN":["1889-1837"],"issn-type":[{"value":"1889-1837","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Renin\u2013angiotensin\u2013aldosterone system blockers effect in chronic kidney disease progression in hypertensive elderly patients without proteinuria: PROERCAN trial","name":"articletitle","label":"Article Title"},{"value":"Hipertensi\u00f3n y Riesgo Vascular","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hipert.2023.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 SEH-LELHA. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}